5mg
Sponsors
The first affiliated hospital, School of Medicine, Zhejiang University, Janssen - Cilag International, Ultragenyx Pharmaceutical Inc., Novartis Pharma AG, OM Pharma SA
Conditions
Bacterial vaginosisGeographic AtrophyGiant cell arteritis (GCA)Glycogen Storage Disease Type Ia (GSDIa)Patients undergoing surgical aortic valve replacement.Recurrent wheezingcardiovascular
Phase 1
Phase 2
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Active, not recruitingCTIS2022-500746-16-00
Start: 2023-08-11Target: 118Updated: 2025-12-15
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing
Active, not recruitingCTIS2024-511083-90-00
Start: 2024-10-03Target: 85Updated: 2025-10-17
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
RecruitingCTIS2022-500747-21-00
Start: 2025-02-27Target: 120Updated: 2025-08-25
Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adenoassociated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
CompletedCTIS2023-508750-25-00
Start: 2022-01-11End: 2025-12-22Target: 30Updated: 2026-01-19
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
SuspendedCTIS2024-510744-31-00
Start: 2021-10-06Target: 243Updated: 2025-12-11
A Phase III, randomized, open label, non-inferiority study comparing the efficacy and safety of furazidin vaginal tablets and clindamycin vaginal cream in the local treatment of bacterial vaginosis
Not yet recruitingCTIS2024-515332-80-00
Target: 600Updated: 2025-12-08